How a secure, sponsor-controlled Digital Research Environment unlocks AI and machine learning across the full drug discovery pipeline — without compromising intellectual property or data governance.
Early-stage drug discovery is one of the most data-intensive, time-pressured, and high-stakes endeavours in modern science. Researchers must evaluate drug targets, model disease progression, characterise patient populations, and screen vast chemical libraries — all before a candidate compound ever reaches a clinical trial.
The sheer scale is daunting. Pharmaceutical sponsors are also under pressure to protect their intellectual property, making most unwilling to place proprietary discovery data on shared platforms — and limiting their ability to benefit from external open-source datasets and multi-institutional collaboration.
Artificial intelligence and machine learning have become credible, increasingly essential tools across the full arc of early drug development. Applications span target identification through to first-in-human dose prediction — with the potential to reduce or replace some in vivo animal testing as model confidence grows.
QSAR and Quantitative Systems Pharmacology (QSP) models help identify the most promising pharmacological targets before resources are committed to laboratory work.
ML algorithms navigate vast chemical spaces to surface bioactive candidates, dramatically accelerating the Design-Make-Test-Analyse (DMTA) cycle that sits at the heart of candidate selection.
Combining preclinical PK/PD data, toxicology results, and real-world patient data, AI-driven model-informed drug development (MIDD) supports more confident first-in-human dose predictions.
Machine learning surfaces prognostic signals within complex, high-dimensional datasets — including imaging and genomic data — that are invisible to conventional statistical methods.
The accuracy of these models depends fundamentally on the volume, quality, and diversity of their training data. This makes the platform on which data is managed and analysed a critical determinant of whether AI/ML delivers on its promise.
The Aridhia Digital Research Environment (DRE) provides pharmaceutical sponsors and research institutions with a cloud-based platform specifically designed for the complexity of drug discovery data workflows — keeping the sponsor in control of data, code, and intellectual property throughout.
Drug discovery generates an exceptionally varied mix of data: in vitro screening results, chemical libraries, PBPK model outputs, clinical pathology images, genomic datasets, and real-world patient data. The DRE is built to ingest and integrate all of these within a governed, auditable workspace.
Unlike outsourced AI platforms, the Aridhia DRE places the sponsor firmly in control. Data, code, and analytical outputs remain within the sponsor’s dedicated environment. This makes it possible to combine proprietary chemical library data with open-source databases — ChEMBL, DrugBank, PubChem — without compromising IP.
The DRE fully integrates AI and machine learning solutions into its workspace environment. Research teams can deploy and run models — including deep learning approaches — within the same secure environment where their data is held. The AIRA framework provides responsible offline LLM support as well as secure pass-through options to external AI services with full audit trails.
The DRE’s federated analysis capabilities — including the open-source Federated Node — and global deployment options allow processing pipelines and analytical tasks to run adjacent to data, and only approved outputs to be shared. This supports consortium-scale research while maintaining compliance.
With the growing availability of AI/ML relevant data — particularly imaging and genomic data — breaking away from static and siloed analytics is essential to accelerate drug discovery and drive innovation. The DRE combines collaborative methods of data analysis with robust AI controls and model deployment (open source, commercial, and proprietary) allow sponsors to pool data and tooling, unlocking new opportunities early stage drug discovery.
Digital research environments provide a mechanism to ingest, curate, integrate and otherwise manage the diverse data types relevant for drug discovery activities, and also provide workspace services from which target sharing and collaboration can occur — providing an alternative with sponsors being in control of the platform, data and predictive algorithms. This favours a dynamic DRE-enabled environment to support drug discovery.
Barrett JS, Eradat Oskoui S, Russell S, Borens A. Front. Pharmacol. 2023;14:1115356 · doi: 10.3389/fphar.2023.1115356
And while regulatory engagement remains essential, the DRE’s collaborative and fully audited capabilities are designed so sponsors can invite regulators into secure workspaces to view data and analyses in situ. Regulators can validate reproducibility in real-time, re-running the same code, on the same data within the same compute infrastructure and verifying that the results and outcomes are reproducible.
| Capability | Benefit for Drug Discovery |
|---|---|
| Secure multi-source data integration | Combine proprietary, open-source, and real-world datasets without IP risk |
| Integrated AI/ML workspace | Run QSAR, QSP, PK/PD, and custom AI models within the same secure environment |
| Federated collection & analysis | Enable multi-site collaboration without moving sensitive data across borders |
| FAIR metadata catalogue | Discover and access datasets through a governed self-service portal with semantic search |
| Full audit trails & provenance | Meet regulatory and ethics requirements — including for AI-generated outputs — with complete lineage |
| Certified infrastructure | Enterprise-grade security accredited to ISO 27001/27701, HITRUST (HIPAA, NIST), and SATRE specifications |
| AIRA AI/ML framework | Responsible generative AI for research workflows — for secure offline or pass-through AI use |
Speak to our team about deploying a secure, AI-integrated environment for your drug discovery data — keeping your IP under your control from day one.
